Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Margolin

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.
The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupD Ross Camidge, Eudocia Q Lee, Nancy U Lin, et al.
NPJ Precision Oncology|November 14, 2023
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastasesGino K In, Jennifer R Ribeiro, Jun Yin, et al.
Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.
Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO groupNancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.
The Lancet. Oncology|June 13, 2015
Response assessment criteria for brain metastases: proposal from the RANO groupNancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2021
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021Susan M Swetter, John A Thompson, Mark R Albertini, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.
The New England Journal of Medicine|August 23, 2018
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainHussein A Tawbi, Peter A Forsyth, Alain Algazi, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupD Ross Camidge, Eudocia Q Lee, Nancy U Lin, et al.
NPJ Precision Oncology|November 14, 2023
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastasesGino K In, Jennifer R Ribeiro, Jun Yin, et al.
Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.
Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
The Lancet. Oncology|September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO groupNancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.
The Lancet. Oncology|June 13, 2015
Response assessment criteria for brain metastases: proposal from the RANO groupNancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2021
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021Susan M Swetter, John A Thompson, Mark R Albertini, et al.
Pageof 10